Tags:HealthHuman
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ
Total raised: $166M

Investors 1

Funding Rounds 2

DateSeriesAmountInvestorsDeal News
25.06.2018Series C$101M--
18.09.2017-$65M--

Mentions in press and media 8

DateTitleDescriptionCategoryAuthorSource
05.10.2021Kaleido Bi...KB295 reached its primary endp...--marketscre...
09.08.2021Kaleido Bi...LEXINGTON, Mass., Aug. 09, 202...--marketscre...
21.04.2021KALEIDO BI...LEXINGTON, Mass. - Kaleido Bio...--marketscre...
29.06.2018Kaleido ra...“We think about the microbiome...--medcitynew...
25.06.2018Kaleido br...Kaleido Biosciences has raked ...Biotech-fiercebiot...
25.06.2018Kaleido Bi...BEDFORD, Mass.--(BUSINESS WIRE...--citybizlis...
18.09.2017Kaleido Bi...Kaleido Biosciences, a Bedford...USA-finsmes.co...
18.09.2017Flagship s...Cambridge, MA-based venture ca...Biotech-fiercebiot...